全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Maximum Recommended Dosage of Lithium for Pregnant Women Based on a PBPK Model for Lithium Absorption

DOI: 10.1155/2012/352729

Full-Text   Cite this paper   Add to My Lib

Abstract:

Treatment of bipolar disorder with lithium therapy during pregnancy is a medical challenge. Bipolar disorder is more prevalent in women and its onset is often concurrent with peak reproductive age. Treatment typically involves administration of the element lithium, which has been classified as a class D drug (legal to use during pregnancy, but may cause birth defects) and is one of only thirty known teratogenic drugs. There is no clear recommendation in the literature on the maximum acceptable dosage regimen for pregnant, bipolar women. We recommend a maximum dosage regimen based on a physiologically based pharmacokinetic (PBPK) model. The model simulates the concentration of lithium in the organs and tissues of a pregnant woman and her fetus. First, we modeled time-dependent lithium concentration profiles resulting from lithium therapy known to have caused birth defects. Next, we identified maximum and average fetal lithium concentrations during treatment. Then, we developed a lithium therapy regimen to maximize the concentration of lithium in the mother’s brain, while maintaining the fetal concentration low enough to reduce the risk of birth defects. This maximum dosage regimen suggested by the model was 400?mg lithium three times per day. 1. Introduction Bipolar disorder, which affects approximately 1% of the population (mostly women), is a type of mood disorder which has periods of manic behavior and periods of depressive behavior. An overly joyful or overexcited state characterizes manic behavior; extremely sad and hopeless states characterize depressive behavior [1]. A standard treatment for bipolar disorder involves treatment with the element lithium, which was the first mood-stabilizing medication approved for treatment of “mania,” which later came to be known as bipolar disorder, in 1970 [2]. The brand names of bipolar lithium treatment drugs are Eskalith and Lithobid, which deliver lithium as lithium carbonate (Li2CO3). The typical size of a dose of lithium drug ranges from 900 to 1800?mg Li2CO3/day (if administered in 2 divided doses a day) and 900 to 2400?mg Li2CO3/day (if administered in 3-4 divided doses a day) [3]. Although the mechanism by which lithium mitigates the symptoms of bipolar disorder is not completely understood, lithium is thought to affect sodium transfer in the brain [4]. High doses can cause lithium poisoning and side effects such as the inability to control movement, blackouts, seizures, hallucinations, severe headaches, and acute renal failure [3, 5]. In women, bipolar disorder typically manifests prior to the age of

References

[1]  National Institute of Mental Health, “Bipolar Disorder,” NIH Publication 09-3679, U.S. Department of Heath and Human Services, National Institutes of Health, 2009.
[2]  C. Kozma, “Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: another clinical report and a review of the literature,” American Journal of Medical Genetics, vol. 132, no. 4, pp. 441–444, 2005.
[3]  Lexi-Comp Online, Formulary and Drug Therapy Guide: Lithium, Lexi-Comp, Hudson, Ohio, USA, 2011.
[4]  L. D. Blake, D. N. Lucas, K. Aziz, A. Castello-Cortes, and P. N. Robinson, “Lithium toxicity and the parturient: case report and literature review,” International Journal of Obstetric Anesthesia, vol. 17, no. 2, pp. 164–169, 2008.
[5]  H. Bendz, S. Sch?n, P. O. Attman, and M. Aurell, “Renal failure occurs in chronic lithium treatment but is uncommon,” Kidney International, vol. 77, no. 3, pp. 219–224, 2010.
[6]  S. T. Blackburn, Maternal, Fetal, & Neonatal Physiology: A Clinical Perspective, Elsevier Saunders, St. Louis, Mo, USA, 2nd edition, 2007.
[7]  F. G. Cunningham, K. J. Leveno, S. Bloom, J. C. Hauth, D. Rouse, and C. Spong, Williams Obstetrics, McGraw-Hill, New York, NY, USA, 23rd edition, 2009.
[8]  U.S. National Library of Medicine. Lithobid (lithium carbonate) tablet, film coated, extended release [Internet]. Daily Med: Current Medication Information, 2011, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ea4ece7f-e81f-48de-b262-577db5b6fe6c.
[9]  K. B. Bischoff, R. L. Dedrick, D. S. Zaharko, and J. A. Longstreth, “Methotrexate pharmacokinetics,” Journal of Pharmaceutical Sciences, vol. 60, no. 8, pp. 1128–1133, 1971.
[10]  C. Timchalk, R. J. Nolan, A. L. Mendrala, D. A. Dittenber, K. A. Brzak, and J. L. Mattsson, “A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans,” Toxicological Sciences, vol. 66, no. 1, pp. 34–53, 2002.
[11]  R. Tardif, G. Charest-Tardif, J. Brodeur, and K. Krishnan, “Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans,” Toxicology and Applied Pharmacology, vol. 144, no. 1, pp. 120–134, 1997.
[12]  H. M. Jones, I. B. Gardner, and K. J. Watson, “Modelling and PBPK simulation in drug discovery,” AAPS Journal, vol. 11, no. 1, pp. 155–166, 2009.
[13]  K. B. Bischoff, R. L. Dedrick, and D. S. Zaharko, “Preliminary model for methotrexate pharmacokinetics,” Journal of Pharmaceutical Sciences, vol. 59, no. 2, pp. 149–154, 1970.
[14]  A. Schoutens, J. Arlet, J. W. M. Gardeniers, and S. P. F. Hughes, Eds., Bone Circulation and Vascularization in Normal and Pathlogical Conditions, vol. 247 of NATO Advanced Science Institutes Series A: Life Sciences, Springer, 1st edition, 1993.
[15]  “The skeletal system,” in Oxford Textbook of Medicine, D. J. Weatherall, J. G. G. Ledingham, and D. A. Warrell, Eds., vol. 3, p. 3066, Oxford University Press, New York, NY, USA, 1996.
[16]  B. Davies and T. Morris, “Physiological parameters in laboratory animals and humans,” Pharmaceutical Research, vol. 10, no. 7, pp. 1093–1095, 1993.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133